{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:24Z","timestamp":1792265064936,"version":"4.4.0"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: To analyze the outcomes of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (SRT) and to study the impact of the sequence between the two modalities. Methods: The authors reviewed the records of 51 patients with 84 BM from NSCLC treated at Institut Curie with IT and SRT. BM were categorized into three groups: \u2018SRT before IT\u2019, \u2018concurrent SRT and IT\u2019, and \u2018SRT after IT.\u2019 Regional progression-free interval (R-PFI) and overall survival (OS) were estimated using the Kaplan\u2013Meier method. Results: After a median follow-up from SRT of 22.5 months (2.7\u201347.3), the 1-year and 2-year OS were 69.7% (95%CI [58.0\u201383.8]) and 44.0% [30.6\u201363.2], respectively. Concerning distant intracranial control, the 1-year and 2-year R-PFI were 40.1% [30.1\u201353.3] and 35.2% [25.1\u201349.4], respectively. Moreover, one-year R-PFI in \u2018SRT before IT\u2019, \u2018concurrent SRT and IT\u2019, and \u2018SRT after IT\u2019 groups were 24.1%, 49.6%, and 34.2%, respectively (p = 0.094). The type of therapeutic sequence did not appear to impact the risk of brain necrosis. Conclusions: The concurrent administration of SRT and IT appeared to offer the best locoregional control, without increasing the risk of toxicity, compared to patients treated with SRT before or after IT.<\/jats:p>","DOI":"10.3390\/biomedicines10092249","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T20:52:25Z","timestamp":1663015945000},"page":"2249","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases"],"prefix":"10.3390","volume":"10","author":[{"given":"Judith","family":"Porte","sequence":"first","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Saint-Martin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Institut Curie, 92210 Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frederic-Moreau","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Massiani","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Institut Curie, 92210 Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bozec","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, 92210 Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-1821","authenticated-orcid":false,"given":"Kim","family":"Cao","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Verrelle","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Otz","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jadaud","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Minsat","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8365-4939","authenticated-orcid":false,"given":"Adriana","family":"Langer","sequence":"additional","affiliation":[{"name":"Department of Imaging, Institut Curie, 92210 Saint-Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Institut du Thorax-Site Curie, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Cr\u00e9hange","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Beddok","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France"},{"name":"Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO U1288, 91401 Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U","article-title":"Brain Metastases. Histology, Multiplicity, Surgery, and Survival","volume":"78","author":"Nussbaum","year":"1996","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","article-title":"A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy versus Observation in Patients with One to Three Brain Metastases from Solid Tumors after Surgical Resection or Radiosurgery: Quality-of-Life Results","volume":"31","author":"Soffietti","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ijrobp.2007.03.048","article-title":"Neurocognitive Function of Patients with Brain Metastasis Who Received Either Whole Brain Radiotherapy plus Stereotactic Radiosurgery or Radiosurgery Alone","volume":"68","author":"Aoyama","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in Patients with Brain Metastases Treated with Radiosurgery or Radiosurgery plus Whole-Brain Irradiation: A Randomised Controlled Trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of Radiosurgery Alone vs Radiosurgery with Whole Brain Radiation Therapy on Cognitive Function in Patients with 1 to 3 Brain Metastases: A Randomized Clinical Trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijrobp.2014.07.002","article-title":"Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy versus WBRT plus Stereotactic Radiosurgery in Patients with 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)","volume":"90","author":"Sperduto","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1470-2045(14)70151-2","article-title":"Stereotactic Radiosurgery for Patients with Brain Metastases","volume":"15","author":"Alongi","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic Radiosurgery for Patients with Multiple Brain Metastases (JLGK0901): A Multi-Institutional Prospective Observational Study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of Local Radiation Therapy in Cancer Immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.3747\/co.25.3839","article-title":"Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"25","author":"Melosky","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for Management of Patients with NSCLC and Brain Metastases: Long-Term Results and Biomarker Analysis from a Non-Randomised, Open-Label, Phase 2 Trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cllc.2021.06.009","article-title":"Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis","volume":"23","author":"Yang","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3340\/jkns.2020.0135","article-title":"Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis: The Role of Gamma Knife Radiosurgery","volume":"64","author":"Lee","year":"2021","journal-title":"J. Korean Neurosurg. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gu\u00e9nol\u00e9, M., Lucia, F., Bourbonne, V., Dissaux, G., Reygagne, E., Goasduff, G., Pradier, O., and Schick, U. (2020). Impact of Concomitant Systemic Treatments on Toxicity and Intracerebral Response after Stereotactic Radiotherapy for Brain Metastases. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07491-z"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijrobp.2005.09.028","article-title":"Conformity Index: A Review","volume":"64","author":"Feuvret","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3171\/sup.2006.105.7.194","article-title":"A Simple Dose Gradient Measurement Tool to Complement the Conformity Index","volume":"105","author":"Paddick","year":"2006","journal-title":"J. Neurosurg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response Assessment Criteria for Brain Metastases: Proposal from the RANO Group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41580-018-0068-0","article-title":"Linking Cellular Stress Responses to Systemic Homeostasis","volume":"19","author":"Galluzzi","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijrobp.2020.04.002","article-title":"Stereotactic Body Radiation Therapy (SBRT) Combined with Immune Check-Point Inhibition (ICI) in Advanced Lung Cancer: Which Metastatic Site Should Be Irradiated to Induce Immunogenic Cell Death?","volume":"108","author":"Eze","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising Efficacy and Reducing Toxicity of Anticancer Radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect When Combined with Anti-CTLA-4 Antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-018-03020-y","article-title":"Concurrent versus Non-Concurrent Immune Checkpoint Inhibition with Stereotactic Radiosurgery for Metastatic Brain Disease: A Systematic Review and Meta-Analysis","volume":"141","author":"Lu","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of Brain Metastases with Stereotactic Radiosurgery and Immune Checkpoint Inhibitors: An International Meta-Analysis of Individual Patient Data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/COC.0000000000000509","article-title":"Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma","volume":"42","author":"Murphy","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","article-title":"Outcomes Targeting the PD-1\/PD-L1 Axis in Conjunction with Stereotactic Radiation for Patients with Non-Small Cell Lung Cancer Brain Metastases","volume":"133","author":"Ahmed","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","article-title":"Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases","volume":"101","author":"Schapira","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical Outcomes of Melanoma Brain Metastases Treated with Stereotactic Radiation and Anti-PD-1 Therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","first-page":"402","article-title":"Immunotherapy Is Associated with Improved Survival and Decreased Neurologic Death after SRS for Brain Metastases from Lung and Melanoma Primaries","volume":"6","author":"Lanier","year":"2019","journal-title":"Neurooncol. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3171\/2019.4.JNS19822","article-title":"Stereotactic Radiosurgery with and without Checkpoint Inhibition for Patients with Metastatic Non-Small Cell Lung Cancer to the Brain: A Matched Cohort Study","volume":"133","author":"Shepard","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","article-title":"Local Tumor Response and Survival Outcomes after Combined Stereotactic Radiosurgery and Immunotherapy in Non-Small Cell Lung Cancer with Brain Metastases","volume":"132","author":"Singh","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_38","first-page":"E465","article-title":"Lesion Response and Intracranial Control of Brain Metastases From Non\u2013Small Cell Lung Cancer after Stereotactic Radiosurgery or Hypofractionated Radiation Therapy Combined with Checkpoint Inhibitors","volume":"99","author":"Imber","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/9\/2249\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:18Z","timestamp":1760142558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/9\/2249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["biomedicines10092249"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10092249","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]}}}